Drug residues in serum of dogs receiving anticancer chemotherapy

Journal of Veterinary Internal Medicine

Volumn 24, Issue 2, 2010, Pages 379-383

  Knobloch, A ^a   Mohring, S A I ^a   Eberle, N ^a   Nolte, I ^a   Hamscher, G ^a   Simon, D ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Canine; Chemotherapy; Cytotoxic; Occupational risk

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG RESIDUE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMISTRY; DOG; DOG DISEASE; LABORATORY PERSONNEL; LYMPHOMA; OCCUPATIONAL EXPOSURE; PROSPECTIVE STUDY; RISK FACTOR; SARCOMA; VETERINARY MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DRUG RESIDUES; LABORATORY PERSONNEL; LYMPHOMA; MAST-CELL SARCOMA; OCCUPATIONAL EXPOSURE; PROSPECTIVE STUDIES; RISK FACTORS; VETERINARIANS;

ANIMALIA; CANIS FAMILIARIS;

EID: 77649165961     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0469.x     Document Type: Article

References (28)

1. Sessink PJM, Boer KA, Scheefhals APH, et al. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Eviron Health 1992;64:105-112.
2. Sessink PJ, Cerna M, Rossner P, et al. Urinary cyclophosph-amide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994;309:193-199.
3. Ensslin AS, Stoll Y, Pethran A, et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994;51:229-233.
4. Ensslin AS, Huber R, Pethran A, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: Urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997;70:205-208.
5. Burgaz S, Karahalil B, Bayrak P, et al. Urinary cyclophosph-amide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999;439:97-104.
6. Pethran A, Schierl R, Hauff K, et al. Uptake of antineoplastic agents in pharmacy and hospital workers. Part I: Monitoring of urinary concentrations. Int Arch Occup Environ Health 2003;76: 5-10.
7. Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: A pilot study. Ann Occup Hyg 2004;48:237-244.
8. Fransman W, Vermeulen R, Kromhout H. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Environ Health 2005;78: 403-412.
9. Fransman W, Peelen S, Hilhorst S, et al. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann Occup Hyg 2007;51:231-239.
10. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Eng J Med 1985;313:1173-1178.
11. Stucker I, Caillard JF, Collin R, et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990;16:102-107.
12. Waksvik H, Klepp O, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981;65: 607-610.
13. Pohlova H, Cerna M, Rossner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res 1986;174:213-217.
14. Milkovic-Kraus S, Horvat D. Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs. Am J Ind Med 1991;19:771-774.
15. Sardas S, Gok S, Karakaya AE. Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs. Toxicol Lett 1991;55:311-315.
16. Goloni-Bertollo EM, Tajara EH, Manzato AJ, Varella-Garcia M. Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer 1992;50:341-344.
17. ECVIMCA. Preventing occupational and environmental exposure to cytotoxic drugs in veterinary medicine, 2nd version, July 2007. Available at: http://www.ecvim-ca.org/guide_lines.html. Accessed May 10, 2009.
18. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948-954.
19. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for highrisk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587.
20. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1390-1396.
21. Hamscher G, Mohring SAI, Knobloch A, et al. Determination of drug residues in urine of dogs receiving anticancer chemotherapy by LC-ESI-MS-MS: Is there an environmental or occupational risk? J Anal Toxicol, in press.
22. Selting KA, et al. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res 2006;67:145-151.
23. IARC. Some Aziridines, N-, S- and O-Mustards and Selenium. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 9, IARC; 1975. Available at: http://monographs.iarc.fr/ENG/Monographs/allmonos90.php
24. IARC. Some Naturally Occurring Substances. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 9, IARC; 1976. Available at: http://monographs.iarc.fr/ENG/Monographs/allmonos90.php
25. IARC. Some Antineoplastic and Immunosuppressive Agents Summary of Data Reported and Evaluation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 26, IARC; 1981. Available at: http://monographs.iarc.fr/ENG/Mono graphs/allmonos90.php
26. IARC. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7. IARC; 1987. Available at: http://monographs.iarc.fr/ENG/Monographs/allmonos90.php
27. Turci R, Sottani C, Spagnoli G, Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: A review of analytical methods. J Chromatogr B 2003;789:169-209.
28. NIOSH. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Available at: http://origin.cdc.gov/niosh/docs/2004-165/pdfs/2004-165sum.pdf. Accessed July 24, 2009.